Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015 (2015), Article ID 260101, 8 pages
http://dx.doi.org/10.1155/2015/260101
Research Article

The Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction

1Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 17, LT-50009 Kaunas, Lithuania
2Department of Cardiology, Lithuanian University of Health Sciences, Eiveniu 2, LT-50009 Kaunas, Lithuania

Received 8 May 2015; Accepted 6 July 2015

Academic Editor: Roberta Palla

Copyright © 2015 Tajinder Kumar Parpugga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. A. Ploplis, “Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease,” Current Drug Targets, vol. 12, no. 12, pp. 1782–1789, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. Y.-Y. Li, “Plasminogen Activator Inhibitor-1 4G/5G gene polymorphism and coronary artery disease in the chinese han population: a meta-analysis,” PLoS ONE, vol. 7, no. 4, Article ID e33511, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. A. D. Michelson, Platelets, Academic Press, San Diego, Calif, USA, 3rd edition, 2013.
  4. R. Mehta and A. D. Shapiro, “Plasminogen activator inhibitor type 1 deficiency,” Haemophilia, vol. 14, no. 6, pp. 1255–1260, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Aso, “Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis,” Frontiers in Bioscience, vol. 12, no. 8, pp. 2957–2966, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Hazra, V. Stepps, A. D. Bhatwadekar et al., “Enhancing the function of CD34+ cells by targeting plasminogen activator inhibitor-1,” PLoS ONE, vol. 8, no. 11, Article ID e79067, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Mertens, A. Verrijken, J. J. Michiels, M. Van der Planken, J. B. Ruige, and L. F. Van Gaal, “Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome,” International Journal of Obesity, vol. 30, no. 8, pp. 1308–1314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M.-C. Alessi, M. Poggi, and I. Juhan-Vague, “Plasminogen activator inhibitor-1, adipose tissue and insulin resistance,” Current Opinion in Lipidology, vol. 18, no. 3, pp. 240–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Xu, H. Wang, Z. Wang, and W. Xiao, “Plasminogen activator inhibitor-1 promotes inflammatory process induced by cigarette smoke extraction or lipopolysaccharides in alveolar epithelial cells,” Experimental Lung Research, vol. 35, no. 9, pp. 795–805, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. E. Tsantes, G. K. Nikolopoulos, P. G. Bagos, S. Bonovas, P. Kopterides, and G. Vaiopoulos, “The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk,” Thrombosis Research, vol. 122, no. 6, pp. 736–742, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. P. E. Morange, N. Saut, M. C. Alessi et al., “Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 10, pp. 2250–2257, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Abboud, L. Ghazouani, S. Saidi et al., “Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/Tissue plasminogen activator levels in myocardial infarction: a case-control study,” Genetic Testing and Molecular Biomarkers, vol. 14, no. 1, pp. 23–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Bouchard, M.-C. Vohl, S. Lebel et al., “Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity,” Obesity Surgery, vol. 20, no. 4, pp. 492–499, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. O. Onalan, G. Balta, A. Oto et al., “Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease,” Journal of Thrombosis and Thrombolysis, vol. 26, no. 3, pp. 211–217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. C. J. M. Doggen, R. M. Bertina, V. M. Cats, P. H. Reitsma, and F. R. Rosendaal, “The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction,” Thrombosis and Haemostasis, vol. 82, no. 1, pp. 115–120, 1999. View at Google Scholar · View at Scopus
  16. I. Juhan-Vague, P. E. Morange, C. Frere et al., “The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study,” Journal of Thrombosis and Haemostasis, vol. 1, no. 11, pp. 2322–2329, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Böttiger, W. Koch, C. Lahn et al., “4G/5G Polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting,” American Heart Journal, vol. 146, no. 5, pp. 855–861, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Sianos, M. A. Morel, AP. Kappetein et al., “The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease,” EuroIntervention, vol. 1, no. 2, pp. 219–227, 2005. View at Google Scholar
  19. W. Ahmed, M. Malik, I. Saeed et al., “Role of tissue plasminogen activator and plasminogen activator inhibitor polymorphism in myocardial infarction,” Molecular Biology Reports, vol. 38, no. 4, pp. 2541–2548, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Ismail, A. A. azeem, M. A. Hamid, S. R. Nowier, and H. Morad, “The role of 4G/5G genetic polymorphism of plasminogen activator inhibitor-1 gene in myocardial infarction among Egyptians,” Life Science Journal, vol. 8, no. 1, pp. 32–39, 2011. View at Google Scholar · View at Scopus
  21. M. S. Akhter, A. Biswas, R. Ranjan et al., “Plasminogen activator inhibitor-1 (PAI-1) Gene 4G/5G promoter polymorphism is seen in higher frequency in the Indian patients with deep vein thrombosis,” Clinical and Applied Thrombosis/Hemostasis, vol. 16, no. 2, pp. 184–188, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Ardissino, P. M. Mannucci, P. A. Merlini et al., “Prothrombotic genetic risk factors in young survivors of myocardial infarction,” Blood, vol. 94, no. 1, pp. 46–51, 1999. View at Google Scholar · View at Scopus
  23. I. Isordia-Salas, A. Leaños-Miranda, I. M. Sainz, E. Reyes-Maldonado, and G. Borrayo-Sánchez, “Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients,” Revista Espanola de Cardiologia, vol. 62, no. 4, pp. 365–372, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. J. Pegoraro and N. Ranjith, “Plasminogen activator inhibitor type 1 (PAI-1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in young Asian Indians with acute myocardial infarction,” Cardiovascular Journal of South Africa, vol. 16, no. 5, pp. 266–270, 2005. View at Google Scholar · View at Scopus
  25. J. P. Corsetti, D. Ryan, A. J. Moss, D. L. Rainwater, W. Zareba, and C. E. Sparks, “Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 3, pp. 548–554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Castro, V. Oviedo-Rodríguez, and L. I. Angel-Chávez, “WRN polymorphisms affect expression levels of plasminogen activator inhibitor type 1 in cultured fibroblasts,” BMC Cardiovascular Disorders, vol. 8, article 5, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Efimov, L. Sokolova, and M. Sokolov, “Diabetes mellitus and coronary heart disease,” Diabetologia Croatica, vol. 30, no. 4, pp. 115–120, 2001. View at Google Scholar
  28. K. S. Fernandes and V. C. Sandrim, “4G/5G polymorphism modulates PAI-1 circulating levels in obese women,” Molecular and Cellular Biochemistry, vol. 364, no. 1-2, pp. 299–301, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Knudsen, T. L. Katzenstein, T. Benfield et al., “Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals,” AIDS, vol. 28, no. 8, pp. 1171–1179, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J. P. Collet, G. Montalescot, E. Vicaut et al., “Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality,” Circulation, vol. 108, no. 4, pp. 391–394, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. H. J. Rapold, V. Grimaudo, P. J. Declerck, E. K. O. Kruithof, and F. Bachmann, “Plasma levels of plasminogen activator inhibitor type 1, β-thromboglobulin, and fibrinopeptide a before, during, and after treatment of acute myocardial infarction with alteplase,” Blood, vol. 78, no. 6, pp. 1490–1495, 1991. View at Google Scholar · View at Scopus
  32. R. Liguori, S. Quaranta, R. Di Fiore, A. Elce, G. Castaldo, and F. Amato, “A novel polymorphism in the PAI-1 gene promoter enhances gene expression. A novel pro-thrombotic risk factor?” Thrombosis Research, vol. 134, no. 6, pp. 1229–1233, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Mehta, P. Mehta, D. Lawson, and T. Saldeen, “Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations,” Journal of the American College of Cardiology, vol. 9, no. 2, pp. 263–268, 1987. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Pastinen, M. Perola, P. Niini et al., “Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population,” Human Molecular Genetics, vol. 7, no. 9, pp. 1453–1462, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Iwai, H. Shimoike, Y. Nakamura, S. Tamaki, and M. Kinoshita, “The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes,” Atherosclerosis, vol. 136, no. 1, pp. 109–114, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Stegnar, P. Uhrin, P. Peternel et al., “The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism,” Thrombosis and Haemostasis, vol. 79, no. 5, pp. 975–979, 1998. View at Google Scholar · View at Scopus